ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59
The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.
The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.
What's Your Reaction?
